Revolution Medicines

RMC-5552 is a small-molecule therapeutic candidate developed by Revolution Medicines for glioblastoma, a highly aggressive primary brain malignancy. The program entered clinical development as a Phase 1 trial but was terminated, with the latest milestone recorded on 2026-05-06. The mechanism of action and specific molecular target have not been disclosed. Revolution Medicines' strategy in glioblastoma appears exploratory at the Phase 1 stage; however, the termination status indicates the program did not advance to later-stage development. No regulatory approvals, label expansions, or commercial milestones have been achieved. The termination of RMC-5552 reflects the high attrition rate typical of early-stage oncology programs, particularly in difficult-to-treat CNS malignancies where blood-brain barrier penetration and efficacy remain significant challenges.

Glioblastoma (WHO Grade IV astrocytoma) remains one of the most lethal human malignancies, with median overall survival of approximately 15 months despite multimodal therapy. The unmet medical need is substantial: current standard-of-care (maximal safe resection, radiotherapy, and temozolomide) has changed little in two decades, and prognosis remains poor. The competitive landscape includes multiple Phase 3 programs (dendritic cell immunotherapy, radiolabeled therapeutics, checkpoint inhibitors, and kinase inhibitors) as well as approved supportive therapies. RMC-5552's termination removes one exploratory option from the pipeline, though numerous alternatives remain in development. The glioblastoma market represents significant commercial opportunity given the high unmet need, but development risk is substantial. The termination of RMC-5552 underscores the difficulty of advancing novel mechanisms in this indication and highlights the competitive pressure from more advanced programs. Patient population remains limited to approximately 10,000–15,000 newly diagnosed cases annually in the United States, constraining commercial scale but supporting premium pricing for effective therapies.

Drug Class: Small-molecule oncology therapeutic

Modality: Small molecule

Indication: Glioblastoma (primary brain malignancy)

Mechanism of Action: Not yet disclosed

Molecular Target: Not yet disclosed

Route of Administration: Not yet disclosed

Sponsor: Revolution Medicines

Development Partner: None disclosed

Related Therapies in Development: Multiple small-molecule kinase inhibitors (cediranib, edotecarin, enzastaurin), immunotherapies (dendritic cell therapy, checkpoint inhibitors), and radiolabeled agents (131I-TLX-101-003, MIN-003-1806) are in Phase 3 development for glioblastoma. Temozolomide remains the standard-of-care chemotherapy.

Patent Status: Not yet disclosed

First Approval: Not applicable; program terminated at Phase 1

FDA Status: Not yet disclosed. RMC-5552 was in Phase 1 development; no regulatory filings, breakthrough designations, or approvals have been reported.

EMA Status: Not yet disclosed.

PMDA (Japan) Status: Not yet disclosed.

NMPA (China) Status: Not yet disclosed.

Development History: RMC-5552 was terminated during Phase 1; no regulatory milestones, designations, or interactions with regulatory authorities have been disclosed. The program did not advance to Phase 2 or later stages.

Strategic Implications: The termination of RMC-5552 reflects the high attrition rate in early-stage oncology development, particularly in CNS malignancies where blood-brain barrier penetration and efficacy remain formidable challenges. Revolution Medicines' decision to terminate suggests either insufficient efficacy signals, tolerability concerns, or strategic resource reallocation toward higher-priority programs.

Competitive Implications: RMC-5552's termination does not materially alter the competitive landscape given the robust Phase 3 pipeline in glioblastoma. The presence of multiple mechanistic approaches (immunotherapy, kinase inhibition, radiolabeled agents) suggests industry confidence in combination strategies and multi-targeted approaches rather than single-agent small molecules.

Future Catalysts: No future milestones are expected for RMC-5552. Competitive catalysts will emerge from Phase 3 readouts in dendritic cell therapy, radiolabeled agents, and kinase inhibitors over the next 2–4 years.

Expected Milestones: None disclosed for RMC-5552. The program is terminated and unlikely to resume.